Vivani Medical Inc. has announced promising results from their recent study involving an exenatide implant designed to reduce liver fat and manage body weight. The study, which was presented in a recent Form 8-K filing, demonstrated that the exenatide implant reduced liver fat by 82% in obese mice after 12 weeks. The findings were consistent with previous investigations using semaglutide injections. Additionally, the exenatide implant, delivered using NanoPortal™ technology, showed durable effects on body weight in healthy Sprague-Dawley rats over a period of 105 days, with some subjects observed for up to 112 days followed by a recovery period. These results highlight the potential of the exenatide implant in addressing obesity-related conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.